IN FORCE Advance Authorisation

DGFT Minutes

Reliability

In force — no superseding record on file.

Document text

Government of India / भारतसरकार Ministry of Commerce and Industry / वाि◌ण rc औरउोगमंालय g 4 Department of Commerce / वाि◌ण wd ि◌वभाग Directorate General of Foreign Trade, Delhi / ि◌वदेश a ापारमहाि◌नदेशालय, ि◌द wi ी VANIJYA BHAWAN, AKBAR ROAD, CENTRAL DELHI, DELHI, 110011 / वाि◌ण wy भवन, अकबररोड, नईि◌द wt ी Email Office : dgft@nic.in , Phone Office : 011-23062777

Minutes of the Norms Committee – 3 Meeting No. NC/3/MEET/Mar/202223/23 dated 17/03/2023 under the Chairmanship of Shri Rajiv Kumar Soni, Jt. DGFT for considering the cases/issues under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2015-20 pertaining to Chemical and Allied products falling under Chapter 29 and 30.

Following members were present in the Meeting:

Sl.<br>No.	Name & Designation	Department
1	Shri Shaish Kumar, Technical–1	Consultant
2	Shri D.N. Mathur, Technical–2	Consultant
3	Shri Nand Lal, Technical–3	Consultant
In attendance
1	Shri Ajay Kumar, Deputy Director	DGFT

The Norms Committee has taken decision only with respect to technical aspect/ wastage norms. While redeeming the application, RAs should check that the applicant has fulfilled all requirements as prescribed in policy/procedure including those in policy circulars issued from time to time or any other provisions under FTP/HBP for issuance of Advance Authorization and regularization of the case.
The committee went through the Minutes of earlier Meeting No. NC/3/MEET/Feb/202223/20 dated 24/02/2023 (actually held on 03/03/2023).

MANUAL CASES

	MANUAL CASES
Case No.	A-01
MeetingNo.	NC/3/MEET/Mar/202223/23
Date	17/03/2023
Firm’s Name	M/s Arch Pharmalabs Limited
HQ F. No.	01/82/050/01264/AM19/DES-III<br>01/82/050/01263/AM19/DES-III<br>01/82/050/01251/AM19/DES-III<br>01/82/050/01249/AM19/DES-III<br>01/82/050/01260/AM19/DES-III<br>01/82/050/01035/AM20/DES-III
RLA F. No.	03/94/040/00126/AM19<br>03/94/040/00160/AM19<br>03/94/040/00141/AM19<br>03/94/040/00162/AM19<br>03/94/040/00158/AM19<br>03/94/040/00888/AM20
Advance Authorization No. and<br>Date	0310822660 dated 27.07.2018, 0310822659 dated 27.07.2018<br>0310822729 dated 31.07.2018, 0310822732 dated 31.07.2018<br>0310822734 dated 31.07.2018,0310834332 dated 20.01.2020
Subject	Request of M/s Arch Pharmalabs Limited for fixation of adhoc norms with<br>the description of Export Product “3a-Hydroxy-7-keto-5b-cholan-24-oic acid<br>(IP-5)” against Advance Authorization No. 0310822660 dated 27.07.2018,<br>0310822659<br>dated<br>27.07.2018,<br>0310822729<br>dated<br>31.07.2018,<br>0310822732 dated 31.07.2018, 0310822734 dated 31.07.2018 and<br>0310834332 dated 20.01.2020
Decision:<br>Dr. M. Asif Musharaaf, General Manager and Shri Suresh P. Gaikwad, Export Executive had<br>attended the Personal Hearing and explained firm’s case.

d 0310834332 dated 20.01.2020| |Decision: Dr. M. Asif Musharaaf, General Manager and Shri Suresh P. Gaikwad, Export Executive had attended the Personal Hearing and explained firm’s case. The Committee heard the explanation of Representatives of the firm and after deliberation, it was decided to change the description of Export Product from ‘URSODEOXYCHOLIOC ACID (UDCA)’ to “3a-Hydroxy-7-keto-5b-cholan-24-oic acid (IP-5)” with the following conditions: (i) Against 100 kg of export obligation of ‘URSODEOXYCHOLIOC ACID (UDCA’ , the export of 106 kg of “3a-Hydroxy-7-keto-5b-cholan-24-oic acid (IP-5)” may be endorsed based on the main raw material Cholic Acid. (ii) Import of input item No. 4 and 6 are not allowed for export of “3a-Hydroxy-7-keto- 5b-cholan-24-oic acid (IP-5)”. Custom duty plus interest etc. will be paid for such import, as per policy. (iii) For any excess of other inputs imported in each licence, the firm will pay custom duty + interest as applicable under the Policy. Following adhoc norms for “3a-Hydroxy-7-keto-5b-cholan-24-oic acid (IP-5)” are approved as under: Export Product Qty Sl. No. Import Items Qty 3a-Hydroxy-7-keto-5b- cholan-24-oic acid (IP-5) 1 kg 1 CHOLICACID 1.32 kg 2 HYDRAZINE HYDRATE(80% SOLUTION) 1.403 kg 3 IEPOX 239 SPRAY DRIED ENZYME POWDER 0.0283kg 4 IEPOX 235 SPRAY DRIED ENZYME POWDER Notrequired 5 IEPOX 152SPRAY DRIED ENZYME POWDER 0.050kg 6 IEPSP

ION) 1.403 kg 3 IEPOX 239 SPRAY DRIED ENZYME POWDER 0.0283kg 4 IEPOX 235 SPRAY DRIED ENZYME POWDER Notrequired 5 IEPOX 152SPRAY DRIED ENZYME POWDER 0.050kg 6 IEPSP 41SPRAY DRIED ENZYME POWDER Notrequired 7 IEP OX 243 SPRAY DRIED ENZYME POWDER 0.034 kg 8 (B-NAD)B-NICOTINAMIDE-ADENINE DINUCLEOTIDE( COENZYME-1) 0.0075 kg Note: Above norms are for regularization and closure purpose only. RA concerned maytake further necessaryaction asper above decision of NC.||

Case No.<br>A-02
MeetingNo.<br>NC/3/MEET/Mar/202223/23
Date<br>17/03/2023
Firm’s Name<br>M/sEmcurePharmaceuticalsLtd.Pune
HQF. No.<br>01/82/162/00012/AM-23/DES-III[P- 35107]
RLA F. No.<br>31/AX04000272AM23
Advance Authorization No. and Date<br>Not issuedyet
Subject<br>Applicability of the Advance Authorization under Self
declaration / Self ratification where SION/adhoc norms
exists(M/s Emcure Pharmaceuticals Ltd.

o. and Date Not issuedyet||| |Subject Applicability of the Advance Authorization under Self||| |declaration / Self ratification where SION/adhoc norms||| |exists(M/s Emcure Pharmaceuticals Ltd. Pune)–reg.||| |Decision: The Committee considered the request of RLA, Pune for clarification on the above|issue and it was|| |observed that earlier the Norms Committee vide its Meeting No.NC/3/MEET/Sep/202223/9 dated 07/10/2022||| |had fixed the adhoc norms for same export product / import item against Advance Authorization No.||| |3111001114 dated 02/03/2022 as under:||| |Export product Qty. Sl. Import items|Qty.|| |No.||| |CIPROBIOTIC FORT TAB 500MG 1 Number 1 CIPROFLOXACIN|555.00 mg|| |(CIPROFLOXACIN TABLETS 500MG)(EACH HYDROCHLORIDE USP||| |FILM COATED TABLET CONTAIN :||| |CIPROFLOXACIN HYDROCHLORIDE USP||| |EQUIVALENT TO CIPROFLOXACIN 500 MG||| |[NET WEIGHT 2577.33 KG])||| |It is clarified that this product does not fall under SION A-412. The above norms were|fixed by taking|| |conversion (as per Drug Manufacturing License) plus 2% standard wastage as per SION A-412.||| |RA concerned may take further necessary action as per above decision of NC.|||

fixed by taking|| |conversion (as per Drug Manufacturing License) plus 2% standard wastage as per SION A-412.||| |RA concerned may take further necessary action as per above decision of NC.|||

Case No.	A-03
MeetingNo.	NC/3/MEET/Mar/202223/23
Date	17/03/2023
Firm’s Name	M/s Bayer Cropscience Limited
HQ F. No.	01/82/050/00460/AM15/DES-III<br>01/82/050/01267/AM15/DES-III<br>01/82/050/00922/AM16/DES-III<br>01/82/050/00415/AM16/DES-III<br>01/82/050/01538/AM16/DES-III
RLA F. No.	03/94/040/00797/AM14<br>03/94/040/00405/AM15<br>03/94/040/00710/AM15<br>03/94/040/00930/AM15<br>03/94/040/00443/AM16
Advance Authorization No. and Date	0310772503 dated 28.02.2014<br>0310788397 dated 26.08.2014<br>0310791177 dated 18.11.2014<br>0310793539 dated 03.02.2015<br>0310800060 dated 05.11.2015
Subject	WP(C) 6442/2018 filed by M/s Bayer Cropscience Limited<br>before Hon’ble High Court of Delhi against the decision taken by<br>Norms Committee-3 fixing the adhoc norms of their five<br>Advance Authorizations
Decision:<br>Shri Chandrasekaran, Manager–Imports & Exports had attended the Personal Hearing and explained<br>firm’s case. The Committee heard the explanation of Representative of the firm decided to call for following<br>information / documents from the firm:<br>(i)<br>Proof of payment of Rs. 5000/- composition fee deposited in RA, Mumbai against each<br>Advance Authorization.<br>(ii)<br>Copy of 4.07 application alongwith technical details as per Annexure to Appendix 4E.

composition fee deposited in RA, Mumbai against each** Advance Authorization. (ii) Copy of 4.07 application alongwith technical details as per Annexure to Appendix 4E.||

Case No.	Case No.	A-04	A-04
MeetingNo.		NC/3/MEET/Mar/202223/23
Date		17/03/2023
Firm’s Name		M/s JodasExpoim Pvt.Ltd.
Subject		Show Cause Notice issued under FT(D&R) Act, 1992 to M/s Jodas Expoim Pvt. Ltd., New<br>Delhi in respect of 26 advance authorizations issued under Para 4.07 A of HBP Vol. I from<br>CLA-NewDelhi
Sl.<br>No.	Hqrs. F. No.	RLA F. No.	Advance Authorization No. and Date
1.	01/82/050/01834/AM19	05/23/040/00081/AM19	0510406732dt. 05.06.2018
2.	01/82/050/02074/AM19	05/23/040/00166/AM19	0510407070 dt. 04.07.2018
3.	01/82/050/01876/AM19	05/23/040/00164/AM19	0510407078 dt. 04.07.2018
4.	01/82/050/01842/AM19	05/23/040/00501/AM18	0510406802dt. 08.06.2018
5.	01/82/050/01841/AM19	05/23/040/00493/AM18	0510406801dt. 08.06.2018
6.	01/82/050/00646/AM19	05/23/040/00214/AM19	0510407421 dt. 02.08.2018
7.	01/82/050/02027/AM19	05/23/040/00295/AM19	0510408025 dt. 08.10.2018
8.	01/82/050/01889/AM19	05/23/040/00183/AM19	0510407217 dt.17.07.2018
9.	01/82/050/02145/AM19	05/23/040/00385/AM19	0510408748dt. 04.12.2018
10.	01/82/050/01836/AM19	05/23/040/00070/AM19	0510406734dt. 05.06.2018
11.	01/82/050/02067/AM19	05/23/040/00334/AM19	0510408268dt. 30.10.2018
12.	01/82/050/01795/AM19	05/23/040/00348/AM18	0510404882 dt. 12.12.2017
13.	01/82/050/01874/AM19	05/23/040/00167/AM19	0510407069 dt.

2/050/02067/AM19|05/23/040/00334/AM19|0510408268dt. 30.10.2018| |12.|01/82/050/01795/AM19|05/23/040/00348/AM18|0510404882 dt. 12.12.2017| |13.|01/82/050/01874/AM19|05/23/040/00167/AM19|0510407069 dt. 04.07.2018| |14.|01/82/050/01998/AM19|05/23/040/00282/AM19|0510407958dt. 03.10.2018| |15.|01/82/050/01802/AM19|05/23/040/00377/AM18|0510405191dt. 02.01.2018| |16.|01/82/050/01971/AM19|05/23/040/00259/AM19|0510407799dt.17.09.2018| |17.|01/82/050/01928/AM19|05/23/040/00231/AM19|0510407551 dt. 20.08.2018| |18.|01/82/050/01970/AM19|05/23/040/00260/AM19|0510407798dt.20.08.2018| |19.|01/82/050/01927/AM19|05/23/040/00232/AM19|0510407550 dt. 20.08.2018| |20.|01/82/050/01808/AM19|05/23/040/00407/AM18|0510405355 dt.15.01.2018| |21.|01/82/050/02298/AM19|05/23/040/00455/AM19|0510409259dt. 09.01.2019| |22.|01/82/050/01875/AM19|05/23/040/00163/AM19|0510407077dt. 04.07.2018| |23.|01/82/050/01840/AM19|05/23/040/00121/AM19|0510406800dt. 04.07.2018| |24.|01/82/050/01885/AM19|05/23/040/00172/AM19|0510407158 dt. 11.07.2018| |25.|01/82/050/01912/AM19|05/23/040/00012/AM19|0510406735dt. 05.06.2018| |26.|01/82/050/02026/AM19|05/23/040/00297/AM19|0510408024dt. 08.10.2018| |Decision: Dr. Srikanth Reddy S, Head RA, Shri G.D. Sreenivasa Rao, Dy. Manager and Shri Sravan Kumar M., AGM(FA) had attendedthe Personal Hearing and explained firm’s case. The Committee heard the explanation of Representatives of the firm and it was decided to defer for the comments of TA.||||

Meeting ended with thanks to Chair and participants

Verbatim extracted text (OCR/PDF). Older scans and tables may show extraction artifacts — verify against the original for anything you act on.

Analysis

No analysis generated for this document yet (analysis runs over brief docs + on-demand). Run build_analysis.py --ids 8006 --apply.